We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Menopause symptom
Personalized treatment from board-certified menopause specialists — online, nationwide, starting at $79/mo.
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA · Last reviewed 2026-05-10
A hot flash is a sudden sensation of intense heat that spreads across the upper body, face, and neck — often followed by sweating, flushing, and a rapid heartbeat. Episodes typically last 1 to 5 minutes and can occur many times a day.
The medical term is "vasomotor symptom" because the cause is in the brain's temperature regulator, the hypothalamus. As estrogen levels fall and fluctuate during perimenopause and menopause, the hypothalamus becomes hypersensitive — narrowing the body's "thermoneutral zone." A small rise in core body temperature that would never trigger anything before now triggers an aggressive cooling response: dilated blood vessels, sweating, and a flush of heat.
Hot flashes are not a minor annoyance. They disrupt sleep, work, public-facing roles, and intimacy. Severe vasomotor symptoms are linked in published research to higher rates of cardiovascular events, more aggressive bone density loss, and measurably worse quality of life.
They are also one of the most well-studied and most treatable symptoms in all of menopause medicine.
Up to 80% of women experience hot flashes during the menopause transition, and on average they continue for 7 to 10 years.
Kindr providers prescribe systemic hormone therapy — typically transdermal estradiol with micronized progesterone — as first-line treatment for moderate to severe hot flashes in patients without contraindications. This is the approach endorsed by NAMS, ACOG, and the Endocrine Society as the most effective treatment available.
For patients who cannot or prefer not to use estrogen, Kindr providers prescribe FDA-approved non-hormonal options including paroxetine (Brisdelle), other SSRIs and SNRIs, gabapentin, and fezolinetant (Veozah) — a newer NK3 receptor antagonist that targets the hypothalamic pathway directly.
Treatment is personalized: dose, delivery (patch, gel, cream), and adjunctive therapy depend on your symptom severity, medical history, and preferences.
Expected timeline: Most patients on appropriately dosed estradiol notice a clear reduction in hot flash frequency and intensity within 2 to 4 weeks, with full effect by 8 to 12 weeks.
Hot flashes are extraordinarily common — they are the single most reported symptom of menopause — but common does not mean acceptable.
For decades women were told to "push through" or that hormone therapy was too risky. The 2022 NAMS Position Statement made the science clear: for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks. You do not have to live with this.
Women with hot flashes often also experience:
night sweats during menopause
Sleep Disruptionsleep disruption during menopause
Anxietyanxiety during menopause
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
On average, vasomotor symptoms continue for 7 to 10 years. About 10% of women experience them for more than a decade. Treatment shortens the symptomatic period dramatically.
They are not life-threatening, but severe and frequent hot flashes are associated in published research with increased cardiovascular risk, accelerated bone loss, and significant quality-of-life impact. They are worth treating.
Lifestyle changes — layered clothing, cool sleeping environments, avoiding alcohol and spicy food triggers, regular exercise — help and matter. For moderate to severe hot flashes they are rarely sufficient on their own.
Yes. Kindr providers can prescribe FDA-approved non-hormonal options including SSRIs, SNRIs, gabapentin, and fezolinetant when hormone therapy is contraindicated or not preferred.
Yes. Kindr providers are board-certified, licensed in all 50 states, and prescribe both hormonal and non-hormonal hot flash treatment via telehealth. Medications ship to your door.
Personalized care from board-certified menopause providers, delivered to your door.
Kindr's primary service for treating hot flashes and related menopause symptoms.
Bioidentical estrogen — first-line treatment for hot flashes, night sweats, vaginal dryness, and bone protection.
ParoxetineThe only SSRI with FDA approval specifically for moderate-to-severe vasomotor symptoms — useful when HRT is not an option.
FezolinetantNon-hormonal NK3 receptor antagonist — the newest mechanism for hot flashes, FDA-approved in 2023.